Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.
This is an entirely free service. No payments are to be made.Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More
Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DISHMAN PHARMA Mar-16 |
MYLAN Dec-14 |
DISHMAN PHARMA/ MYLAN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 374 | 4,254 | - | |
Low | Rs | 129 | 2,998 | - | |
Sales per share (Unadj.) | Rs | 197.8 | 1,456.2 | - | |
Earnings per share (Unadj.) | Rs | 21.2 | 175.4 | - | |
Cash flow per share (Unadj.) | Rs | 34.7 | 282.4 | - | |
Dividends per share (Unadj.) | Rs | 2.00 | 0 | - | |
Dividend yield (eoy) | % | 0.8 | 0 | - | |
Book value per share (Unadj.) | Rs | 179.9 | 723.9 | - | |
Shares outstanding (eoy) | m | 80.69 | 378.37 | - | |
Bonus/Rights/Conversions | - | OI | - | ||
Price / Sales ratio | x | 1.3 | 2.5 | 51.1% | |
Avg P/E ratio | x | 11.9 | 20.7 | 57.4% | |
P/CF ratio (eoy) | x | 7.2 | 12.8 | 56.4% | |
Price / Book Value ratio | x | 1.4 | 5.0 | 27.9% | |
Dividend payout | % | 9.4 | 0 | - | |
Avg Mkt Cap | Rs m | 20,306 | 1,371,817 | 1.5% | |
No. of employees | `000 | 0.8 | 25.0 | 3.3% | |
Total wages/salary | Rs m | 5,355 | 0 | - | |
Avg. sales/employee | Rs Th | 19,252.7 | 22,039.1 | 87.4% | |
Avg. wages/employee | Rs Th | 6,459.5 | 0 | - | |
Avg. net profit/employee | Rs Th | 2,064.1 | 2,655.0 | 77.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 15,961 | 550,976 | 2.9% | |
Other income | Rs m | 265 | -3,212 | -8.3% | |
Total revenues | Rs m | 16,226 | 547,765 | 3.0% | |
Gross profit | Rs m | 4,103 | 137,030 | 3.0% | |
Depreciation | Rs m | 1,091 | 40,467 | 2.7% | |
Interest | Rs m | 944 | 23,766 | 4.0% | |
Profit before tax | Rs m | 2,334 | 69,586 | 3.4% | |
Minority Interest | Rs m | 0 | -285 | 0.0% | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 624 | 2,926 | 21.3% | |
Profit after tax | Rs m | 1,711 | 66,374 | 2.6% | |
Gross profit margin | % | 25.7 | 24.9 | 103.4% | |
Effective tax rate | % | 26.7 | 4.2 | 635.5% | |
Net profit margin | % | 10.7 | 12.0 | 89.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 11,018 | 484,381 | 2.3% | |
Current liabilities | Rs m | 9,517 | 378,689 | 2.5% | |
Net working cap to sales | % | 9.4 | 19.2 | 49.0% | |
Current ratio | x | 1.2 | 1.3 | 90.5% | |
Inventory Days | Days | 110 | 78 | 141.5% | |
Debtors Days | Days | 35 | 107 | 32.5% | |
Net fixed assets | Rs m | 16,304 | 127,467 | 12.8% | |
Share capital | Rs m | 161 | 19,484 | 0.8% | |
Net worth | Rs m | 14,516 | 273,890 | 5.3% | |
Long term debt | Rs m | 4,189 | 409,164 | 1.0% | |
Total assets | Rs m | 29,805 | 1,103,202 | 2.7% | |
Interest coverage | x | 3.5 | 3.9 | 88.4% | |
Debt to equity ratio | x | 0.3 | 1.5 | 19.3% | |
Sales to assets ratio | x | 0.5 | 0.5 | 107.2% | |
Return on assets | % | 8.9 | 8.2 | 109.0% | |
Return on equity | % | 11.8 | 24.2 | 48.6% | |
Return on capital | % | 17.5 | 13.6 | 128.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,786 | 72,426 | 3.8% | |
From Investments | Rs m | -1,529 | -57,117 | 2.7% | |
From Financial Activity | Rs m | -941 | -19,084 | 4.9% | |
Net Cashflow | Rs m | 316 | -3,775 | -8.4% |
Compare DISHMAN PHARMA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
Compare DISHMAN PHARMA With: J.B.CHEMICALS ELDER PHARMA ALEMBIC LTD GSK PHARMA NOVARTIS
| |
The stock markets are very volatile these days. As the Tanushree Bannerjee, the co-head of research here at Equitymaster puts it, stock markets are two-faced.
Should you subscribe to the IPO of Aster DM Healthcare Ltd?
Should you subscribe to the IPO of Shalby Ltd?
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Exposure to high margin specialty products offers promising growth prospects.
More Views on NewsTanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.
Managements of companies can create or ruin their fortunes. Why is management quality such an important factor in valuing businesses? Read on to find out...
A roundtable on the 18th of January 2019 had investors with billions of dollars of investment kitty.
This is the trick to following super investors and not losing money.
While selecting good businesses is relatively easy task in a bearish phase, where most people fail is in having enough patience to hold the quality stocks until recovery.
More
| |